Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor

Mitochondria are key tumor drivers, but their suitability as a therapeutic target is unknown. Here, we report on the preclinical characterization of Gamitrinib (GA mitochondrial matrix inhibitor), a first-in-class anticancer agent that couples the Heat Shock Protein-90 (Hsp90) inhibitor 17-allylamin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayat, Umar, Elliott, Gary T., Olszanski, Anthony J., Altieri, Dario C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820820/
https://www.ncbi.nlm.nih.gov/pubmed/35129069
http://dx.doi.org/10.1080/15384047.2022.2029132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820820/
https://www.ncbi.nlm.nih.gov/pubmed/35129069
http://dx.doi.org/10.1080/15384047.2022.2029132

Ejemplares similares